all report title image
  • Published On : Jan 2022
  • Code : CMI4891
  • Industry : Medical Devices
  • Pages : 90
  • Formats :

To achieve a therapeutic effect in humans and animals, drug delivery is the method of delivering a pharmaceutical compound. Nasal and pulmonary routes are gaining increasing importance of drug delivery for the treatment on humans. For peptide and protein therapeutics these routes of drug delivery provide promising alternative to parenteral drug delivery.

The use of injectable drug delivery with advent of self-injection devices such as auto-injectors, pen-injectors, has made administration of drugs easy for patients at home without any medical assistance.

Figure 1. Middle East and Asia Injectable Drugs Market Value (US$ Mn), By Product Type, 2021

Middle East and Asia Injectable Drugs  | Coherent Market Insights

Figure 1.1 Middle East and Asia Injectable Drugs Market Value (US$ Mn), By Product Type, 2028

Middle East and Asia Injectable Drugs  | Coherent Market Insights

CMI table icon

Middle East and Asia Injectable Drugs Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 4,15,000 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 8.2% 2028 Value Projection: US$ 7,23,164 Mn
Geographies covered:
  • Middle East: Algeria, Bahrain, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Palestine, Qatar, Saudi Arabia, Syria, Tunisia, Turkey, United Arab Emirates, and Yemen.
  • Asia: Afghanistan, Armenia, Azerbaijan, Bahrain, Bangladesh, Bhutan, Brunei, Cambodia, China, Georgia, India, Indonesia, Japan, Jordan, Kazakhstan, Kuwait, Kyrgyzstan, Malaysia, Maldives, Mongolia, Myanmar (Burma), Nepal, North Korea, Oman, Pakistan, Philippines, Qatar, Russia, Saudi Arabia, Singapore, South Korea, Sri Lanka, Syria, Tajikistan, Thailand, Timor-Leste (East Timor), Turkey, Turkmenistan, Uzbekistan, Vietnam.
Segments covered:
  • By Product Type: Pre-filled Syringes, Auto-injectors, Pre-filled Pens, Pre-mixed IV Bags, Others
  • By Drug Class: Anesthesia, Antibiotics, Antidotes, Antiemetic, Anti-infective, Anti-thrombolytic, Muscle Relaxant, Non Opioids, Opioids, Sedatives, Others
  • By Route of Administration: Intramuscular (IM), Intravenous (IV), Subcutaneous (SC), Others (Epidural and Intrathecal)
  • By End Users: Hospitals, Clinics, Ambulatory Surgery Centers
Companies covered:

Kalbe Farma, Takeda pharmaceuticals Co. Ltd., Livzon Pharmaceutical Group, Inc., Sun Pharmaceutical Industries, Ltd., Pfizer, Inc., Sanofi, Novartis, Tabuk, Novo Nordisk,  GlaxoSmithKline plc, AstraZeneca, and Gerresheimer AG

Growth Drivers:
  • Increase in technology advancement
  • Innovations and ongoing R&Ds on injectable drug delivery systems
Restraints & Challenges:
  • Various drawbacks in healthcare system in Middle East

Figure 2. Middle East and Asia Injectable Drugs Market Value (US$ Mn), By Route of Administration, 2021

Middle East and Asia Injectable Drugs  | Coherent Market Insights

Figure 2.1. Middle East and Asia Injectable Drugs Market Value (US$ Mn), By Route of Administration, 2028

Middle East and Asia Injectable Drugs  | Coherent Market Insights

Middle East and Asia Injectable Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 3.3 million new cases were reported, across the globe.

The COVID-19 pandemic and lockdown in various countries across the globe has negatively impacted the financial status of businesses across all sectors. Likewise, COVID-19 pandemic is expected to have a negative impact on Middle East and Asia injectable drugs market

Even if the COVID-19 pandemic has caused a huge disruption in global pharmaceutical supply chain, in Saudi COVID-19 impact was largely manageable in healthcare institutions. There are various reasons that can attribute between the effective exchange programs within the hospitals and huge increase in public healthcare such as technological advancements, ageing populations, changing disease patterns.

Middle East and Asia Injectable Drugs Market - Restraint

In Middle East, the diseases which are non-communicable are causing premature deaths such as heart disease (45%) and stroke (36%). The growing burden of non-communicable diseases in the region is increasing because of improper diet, smoking, high B.P., and huge body mass.

The market forces are to be taken over because of government failure to provide comprehensive healthcare services. So this has changed it in a commodity with curative impact rather than just preventive. The development of health systems had been driven by economic opportunities for providers.  

Key Players

Major players operating in the Middle East and Asia Injectable Drugs Market include Kalbe Farma, Takeda pharmaceuticals Co. Ltd., Livzon Pharmaceutical Group, Inc., Sun Pharmaceutical Industries, Ltd., Pfizer, Inc., Sanofi, Novartis, Tabuk, Novo Nordisk, GlaxoSmithKline plc, AstraZeneca, and Gerresheimer AG

Injectable drug delivery is considered as the most effective route of administration for the effective delivery of drugs to the targeted site. Injectable delivery facilitates rapid absorption of drug from various route of administration such as subcutaneous, intravenous, and intramuscular. Injectable delivery increases the bioavailability of the drug at the systemic circulation. The increasing prevalence of chronic diseases, technological advancements, demand for individual therapy, awareness regarding drug metabolism among the population, and requirement of controlled drug release are the major factors driving the growth of the Middle East and Asia injectable drugs market.

Middle East and Asia injectable drugs market is estimated to be valued at US$ 4,15,000 Mn in 2021 and is expected to increase to US$ 7,23,164 Mn by 2028, witnessing a CAGR of 8.2% during the forecast period.

Market Dynamics

Increase in technology advancement, increasing government initiatives in healthcare sector of Middle East, innovations and ongoing R&Ds on injectable drug delivery systems and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive the growth of the Middle East and Asia injectable drugs market.

As per the article Bevan Brittan, 2020, The Middle East is seeing a boom in healthcare sector. Aging populations, lengthening life expectations, and different lifestyle are the factors driving the market growth. The opportunities are leading to new models of care and out of hospital facilities because of the focus on prevention and not just simple treatment. Encompassing the primary, community and secondary care, the Saudi Arabia has embarked to build a new healthcare system.

Key features of the study:

  • This report provides in-depth analysis of the Middle East and Asia injectable drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the Middle East and Asia injectable drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Kalbe Farma, Takeda pharmaceuticals Co. Ltd., Livzon Pharmaceutical Group, Inc., Sun Pharmaceutical Industries, Ltd., Pfizer, Inc., Sanofi, Novartis, Tabuk, Novo Nordisk, GlaxoSmithKline plc, AstraZeneca, and Gerresheimer AG
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The Middle East and Asia injectable drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Middle East and Asia injectable drugs market

Detailed Segmentation:

  • Middle East and Asia Injectable Drugs Market, By Product Type:
    • Pre-filled Syringes
      • Vaccines
      • Blood Stimulants
      • Biologics
      • Others
    • Auto-injectors
    • Pre-filled Pens
    • Pre-mixed IV Bags
      • Sedative Products (Sedation)
      • Anesthesia Products (Anesthesia)
      • Pain Management Products (Post-operative analgesic pain management)
      • Chemotherapy Products (Chemotherapy)
      • Antibacterial Products (Infectious diseases)
      • Electrolyte and Nutrition Products (Electrolyte and Nutrition)
    • Others
  • Middle East and Asia Injectable Drugs Market, By Route of Administration:
    • Intramuscular (IM)
    • Intravenous (IV)
    • Subcutaneous (SC)
    • Others (Epidural and Intrathecal)
  • Middle East and Asia Injectable Drugs Market, By Drug Class:
    • Anesthesia
    • Antibiotics
    • Antidotes
    • Antiemetic
    • Anti-infective
    • Anti-thrombolytic
    • Muscle Relaxant
    • Non Opioids
    • Opioids
    • Sedatives
    • Others
  • Middle East and Asia Injectable Drugs Market, By End Users:
    • Hospitals
    • Clinics
    • Ambulatory Surgery Centers
  • Company Profiles
    • Kalbe Farma*
      • Company highlights
      • Product Portfolio
      • Key Highlights
      • Financial performance
      • Strategies
    • Takeda pharmaceuticals Co. Ltd.
    • Livzon Pharmaceutical Group, Inc.
    • Sun Pharmaceutical Industries, Ltd.
    • Pfizer, Inc.
    • Sanofi
    • Novartis
    • Tabuk
    • Novo Nordisk
    • GlaxoSmithKline plc
    • AstraZeneca
    • Gerresheimer AG

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The Middle East and Asia Injectable Drugs market is estimated to be valued at US$ 4,15,000 million in 2021 and is expected to exhibit a CAGR of 8.2% over the forecast period (2021-2028).
Increase in technology advancement, increasing government initiatives in healthcare sector of Middle East, innovations and ongoing R&Ds on injectable drug delivery systems are the major factors which are expected to drive the market growth over the forecast period. 
Pre-filled syringes is expected to hold major market share. Pre-filled syringes segment is estimated to account for 8.2% market share in 2021, and is expected to account for 8.2% by 2028.
Major factors hampering growth of the market include various drawbacks in healthcare system in Middle East.
Major players operating in the market include Kalbe Farma, Takeda pharmaceuticals Co. Ltd., Livzon Pharmaceutical Group, Inc., Sun Pharmaceutical Industries, Ltd., Pfizer, Inc., Sanofi, Novartis, Tabuk, Novo Nordisk, GlaxoSmithKline plc, AstraZeneca, and Gerresheimer AG

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo